{"title":"眼体长的临床基础和治疗结果","authors":"Feyza Çalış, Kaan Gündüz, Işınsu Kuzu, Esra Erden","doi":"10.4274/tjo.75436","DOIUrl":null,"url":null,"abstract":"Yazışma Adresi/Address for Correspondence: Dr. Feyza Çalış Ankara Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye Gsm: +90 312 595 62 66 E-posta: feyzacalis@hotmail.com Geliş Tarihi/Received: 22.07.2013 Kabul Tarihi/Accepted: 15.04.2014 Objectives: To evaluate the clinical characteristics and treatment results in patients who were diagnosed to have ocular adnexal lymphoma (OAL). Materials and Methods: We retrospectively evaluated twenty-six patients with OAL who were diagnosed and treated in the Oncology Service, Department of Ophthalmology, Ankara University School of Medicine, between October 1998 and 2011. Results: There were 16 women and 10 men. The mean age was 61.6 (range: 27-76) years. The tumor affected the conjunctiva in 10 patients, the orbit in 8 patients, eyelids in 3 patients, the lacrimal gland in 3 patients, the conjunctiva and the orbit in 2 patients. A diagnostic incisional biopsy or subtotal tumor excision was generally performed. Total surgical excision, if possible, was performed in some cases. Histopathologically, all the tumors were diagnosed as B cell non-Hodgkin lymphoma. External beam radiotherapy (EBRT) was given in 19 patients, and chemotherapy in three patients because of systemic involvement. Combination of EBRT and chemotherapy was given in two patients. Three patients underwent total surgical excision. Orbital recurrence was detected in one patient during the mean follow-up period of 27 months (range: 2-72 months). At the end of the follow-up period, five cases developed keratopathy secondary to radiotherapy. One patient died from intracranial lymphoma involvement. Conclusion: OALs usually have favorable prognosis with congenial treatment. EBRT is the preferred treatment in localized periorbital disease, and chemotherapy is used in cases with systemic involvement. (Turk J Ophthalmol 2014; 44: 374-8)","PeriodicalId":46049,"journal":{"name":"Turk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2014-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Oküler Adneksal Lenfomalı Olgularda Klinik Bulgular ve Tedavi Sonuçları\",\"authors\":\"Feyza Çalış, Kaan Gündüz, Işınsu Kuzu, Esra Erden\",\"doi\":\"10.4274/tjo.75436\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Yazışma Adresi/Address for Correspondence: Dr. Feyza Çalış Ankara Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye Gsm: +90 312 595 62 66 E-posta: feyzacalis@hotmail.com Geliş Tarihi/Received: 22.07.2013 Kabul Tarihi/Accepted: 15.04.2014 Objectives: To evaluate the clinical characteristics and treatment results in patients who were diagnosed to have ocular adnexal lymphoma (OAL). Materials and Methods: We retrospectively evaluated twenty-six patients with OAL who were diagnosed and treated in the Oncology Service, Department of Ophthalmology, Ankara University School of Medicine, between October 1998 and 2011. Results: There were 16 women and 10 men. The mean age was 61.6 (range: 27-76) years. The tumor affected the conjunctiva in 10 patients, the orbit in 8 patients, eyelids in 3 patients, the lacrimal gland in 3 patients, the conjunctiva and the orbit in 2 patients. A diagnostic incisional biopsy or subtotal tumor excision was generally performed. Total surgical excision, if possible, was performed in some cases. Histopathologically, all the tumors were diagnosed as B cell non-Hodgkin lymphoma. External beam radiotherapy (EBRT) was given in 19 patients, and chemotherapy in three patients because of systemic involvement. Combination of EBRT and chemotherapy was given in two patients. Three patients underwent total surgical excision. Orbital recurrence was detected in one patient during the mean follow-up period of 27 months (range: 2-72 months). At the end of the follow-up period, five cases developed keratopathy secondary to radiotherapy. One patient died from intracranial lymphoma involvement. Conclusion: OALs usually have favorable prognosis with congenial treatment. EBRT is the preferred treatment in localized periorbital disease, and chemotherapy is used in cases with systemic involvement. (Turk J Ophthalmol 2014; 44: 374-8)\",\"PeriodicalId\":46049,\"journal\":{\"name\":\"Turk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2014-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/tjo.75436\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/tjo.75436","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
Yazışma Adresi/通信地址:Dr. Feyza Çalış Ankara Üniversitesi Tıp fak ltesi, Göz Hastalıkları Anabilim dalyi, Ankara,土耳其 Gsm: +90 312 595 62 66 E-posta: feyzacalis@hotmail.com gelikan Tarihi/接收:22.07.2013喀布尔Tarihi/接收:15.04.2014目的:评价诊断为眼附件淋巴瘤(OAL)患者的临床特征和治疗效果。材料和方法:我们回顾性评估了1998年10月至2011年10月期间在安卡拉大学医学院眼科肿瘤科诊断和治疗的26例OAL患者。结果:女性16例,男性10例。平均年龄61.6岁(27 ~ 76岁)。肿瘤累及结膜10例,眼眶8例,眼睑3例,泪腺3例,结膜及眼眶2例。通常进行诊断性切口活检或肿瘤次全切除。如果可能的话,在一些病例中进行了完全手术切除。组织病理学均诊断为B细胞非霍奇金淋巴瘤。19例患者接受外束放疗(EBRT), 3例患者因全身受累而接受化疗。2例患者采用EBRT联合化疗。3例患者接受了全手术切除。1例患者眼眶复发,平均随访27个月(2-72个月)。随访结束时,5例发生放疗后继发角膜病变。1例患者死于颅内淋巴瘤累及。结论:经适当治疗,OALs预后良好。EBRT是局部眶周疾病的首选治疗方法,而化疗则用于全身累及的病例。(土耳其眼科杂志2014;44: 374 - 8)
Oküler Adneksal Lenfomalı Olgularda Klinik Bulgular ve Tedavi Sonuçları
Yazışma Adresi/Address for Correspondence: Dr. Feyza Çalış Ankara Üniversitesi Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye Gsm: +90 312 595 62 66 E-posta: feyzacalis@hotmail.com Geliş Tarihi/Received: 22.07.2013 Kabul Tarihi/Accepted: 15.04.2014 Objectives: To evaluate the clinical characteristics and treatment results in patients who were diagnosed to have ocular adnexal lymphoma (OAL). Materials and Methods: We retrospectively evaluated twenty-six patients with OAL who were diagnosed and treated in the Oncology Service, Department of Ophthalmology, Ankara University School of Medicine, between October 1998 and 2011. Results: There were 16 women and 10 men. The mean age was 61.6 (range: 27-76) years. The tumor affected the conjunctiva in 10 patients, the orbit in 8 patients, eyelids in 3 patients, the lacrimal gland in 3 patients, the conjunctiva and the orbit in 2 patients. A diagnostic incisional biopsy or subtotal tumor excision was generally performed. Total surgical excision, if possible, was performed in some cases. Histopathologically, all the tumors were diagnosed as B cell non-Hodgkin lymphoma. External beam radiotherapy (EBRT) was given in 19 patients, and chemotherapy in three patients because of systemic involvement. Combination of EBRT and chemotherapy was given in two patients. Three patients underwent total surgical excision. Orbital recurrence was detected in one patient during the mean follow-up period of 27 months (range: 2-72 months). At the end of the follow-up period, five cases developed keratopathy secondary to radiotherapy. One patient died from intracranial lymphoma involvement. Conclusion: OALs usually have favorable prognosis with congenial treatment. EBRT is the preferred treatment in localized periorbital disease, and chemotherapy is used in cases with systemic involvement. (Turk J Ophthalmol 2014; 44: 374-8)